Cite
Bortezomib maintenance after R‐CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.
MLA
Doorduijn, Jeanette K., et al. “Bortezomib Maintenance after R‐CHOP, Cytarabine and Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Mantle Cell Lymphoma, Results of a Randomised Phase II HOVON Trial.” British Journal of Haematology, vol. 190, no. 3, Aug. 2020, pp. 385–93. EBSCOhost, https://doi.org/10.1111/bjh.16567.
APA
Doorduijn, J. K., Zijlstra, J. M., Lugtenburg, P. J., Kersten, M. J., Böhmer, L. H., Minnema, M. C., MacKenzie, M. A., van Marwijk Kooij, R., Jongh, E., Snijders, T. J. F., Weerdt, O., Gelder, M., Hoogendoorn, M., Leys, R. B. L., Kibbelaar, R. E., Jong, D., Chitu, D. A., Van’t Veer, M. B., & Kluin, N. H. C. (2020). Bortezomib maintenance after R‐CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial. British Journal of Haematology, 190(3), 385–393. https://doi.org/10.1111/bjh.16567
Chicago
Doorduijn, Jeanette K., Josee M. Zijlstra, Pieternella J. Lugtenburg, Marie Josee Kersten, Lara H. Böhmer, Monique C. Minnema, Marius A. MacKenzie, et al. 2020. “Bortezomib Maintenance after R‐CHOP, Cytarabine and Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Mantle Cell Lymphoma, Results of a Randomised Phase II HOVON Trial.” British Journal of Haematology 190 (3): 385–93. doi:10.1111/bjh.16567.